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Brazilian criteria for LTBI treatment strongly suggests that a
change on these criteria could have a direct impact on TB
control.14th International Congress on Infectious Diseases (ICID) Abs
are focal nodes in biosynthetic network of virulent lipids,
inhibitors directed against these proteins provide a unique
multi-pronged approach of simultaneously disrupting several
pathways in lipid metabolism. Our study illustrate how obli-
gate pathogens like Mtb have evolved such novel themes
of functional versatility to generate unusual metabolites.
We also reveal possible evolutionary path traced by FAALs
from omnipresent fatty acyl CoA ligases. Furthermore, our
study also provide credence to the ‘systems pharmacology’
approach for drug discovery.
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Tuberculosis (TB) remains one of the major causes of
death from a single infectious agent worldwide. Of great
concern for TB control is the emergence of drug resistance.
Since there is no cure for some multidrug-resistant strains of
Mycobacterium tuberculosis, there is concern that they may
spread around the world, stressing the need for additional
control measures, such as new diagnostics, better drugs for
treatment, and a more effective vaccine. Pulmonary TB can
be diagnosed by its symptoms, chest radiography, sputum
smear microscopy and by cultivation of M. tuberculosis,
which is considered as the gold standard. Recent advances
in molecular biology and molecular epidemiology, and a bet-
ter understanding of the molecular basis of drug resistance
in TB, have provided new tools for rapid diagnosis; how-
ever, the high cost of most of these techniques, and their
requirement for sophisticated equipment and skilled person-
nel have precluded their implementation on a routine basis,
especially in low-income countries. Other nonconventional
diagnostic approaches proposed include the search for bio-
chemical markers, detection of immunological response and
early detection of M. tuberculosis by methods other than
colony counting. In the present mini review, some of these
approaches will be reviewed and the feasibility for their
implementation in diagnostic laboratories will be discussed.
However, with the resurgence of interest in the develop-
ment of new tools for TB control, and the recent inﬂux of
funding and political support, it is likely that the next few
years will see the introduction of new diagnostic tools into
routine TB control programs and particularly in high disease
burden, and resource-poor countries.
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Current chemotherapy for tuberculosis leaves consid-
rable room for improvement. Major objectives include
hortening the duration of therapy necessary for cure,
mproving the efﬁcacy of intermittent treatment regimens,
nd preventing the development of drug resistance. Bet-
er understanding of the pharmacodynamic relationship
etween drug exposure and drug effect will identify strate-
ies for optimizing drug effect in order to achieve these
bjectives, thereby informing pre-clinical drug develop-
ent, clinical trial design and clinical practice. Recent work
n in vitro and animal models involving both new and exist-
ng antituberculosis drugs will be reviewed and discussed in
his context.
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Brazil is a country in South America with a total popu-
ation of 191 million of people (81% urban; 19% rural) with
n estimated incidence of 92,000 new cases of tuberculo-
is (TB) yearly (data from 2007). Treatment of latent TB
nfection (LTBI) in Brazil is currently recommended only
n the case of contacts of pulmonary smear-positive TB
atients aged % 15 years with a tuberculin skin test (TST)
‘10mm and no previous bacilli Calmette-Guérin (BCG) vac-
ination or with a TST’’ 15mm regardless of previous BCG
accination. However, a recent retrospective cohort study
valuating contacts aged ‘‘15 years who did not meet the
razilian criteria for LTBI treatment shown a TB incidence
f 3.2% (22/667), with an estimated TB rate of 1,649 per 100
00 population. The risk of TB was greater among the 349
ontacts with TST’’ 5mm (5.4%) compared to the 318 con-
acts with TST < 5mm (0.9%; RR 6.04, 95%CI 1.7—20.6). The
igh incidence of TB among contacts who did not meet theoi:10.1016/j.ijid.2010.02.2218
